Brief: Gri Bio Receives Authorization To Conduct Phase 2A Biomarker Study Evaluating Gri-0621 In Australia
26/09/2024 13:17
Sept 26 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO RECEIVES AUTHORIZATION TO CONDUCT PHASE 2A
BIOMARKER
STUDY EVALUATING GRI-0621 IN AUSTRALIA
* GRI BIO INC: ON TRACK TO REPORT INTERIM DATA Q4 2024 AND
TOPLINE
DATA Q1 2025
Source text for Eikon: ID:nGNX1vwHJn
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027